Mativ Holdings (MATV) AI Stock Analysis

Company Guidance

Guidance highlights: Mativ expects Q2 adjusted EBITDA to be down a mid-single-digit percentage versus a strong prior year (driven largely by near-term health care volume weakness) while reiterating that pricing actions taken in January and March are intended to fully offset revised 2026 input cost inflation now estimated at $40–$50 million (up from a prior $20–$25 million view); the company is on track for $15–$20 million of cost savings in 2026 after realizing nearly $20 million in 2025, and continues to prioritize debt reduction toward a 2.5–3.5x net leverage goal (Q1 net leverage was 4.1x with net debt ≈ $954 million and liquidity ≈ $499 million); management expects annual interest expense of roughly $76 million, Q1 free cash flow was a use of $7 million (improving >$22 million YoY) against record 2025 free cash flow of $94 million with seasonally strongest cash generation expected in Q2–Q3, and the company plans modest incremental 2026 investments (~$10 million working capital and ~$5 million additional CapEx); Q1 metrics to frame this guidance: net sales $480 million, adjusted EBITDA $47.5 million (margin 9.9%, +220 bps), FAM sales $188 million with adj. EBITDA $27 million (margin 14.6%, +430 bps), SAS sales $291 million with adj. EBITDA ~ $31 million (margin 10.5%, +160 bps), and segment margins were restated ~100 bps lower after centralized cost allocations (consolidated adj. EBITDA unchanged).